(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016894 A1

(51) International Patent Classification[7]: C07D 239/48, 405/12, 403/12, 401/12, 401/14, A61K 31/506, 35/00, A61P 37/00, 29/00, C07D 401/14, 405/14

(21) International Application Number:
PCT/EP2004/009099

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0319227.5 15 August 2003 (15.08.2003) GB
0322370.8 24 September 2003 (24.09.2003) GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant *(for all designated States except US)*: **IRM LLC**; Sofia House, 48 Church Street, Hamilton HM XL (BM).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GARCIA-ECHEVERRIA, Carlos** [ES/CH]; Engelgasse 126, CH-4052 Basel (CH). **KANAZAWA, Takanori** [JP/JP]; 27-8-203, Higashi-arai, Tsukuba-shi, Ibaraki Pref. 305-0033 (JP). **KAWAHARA, Eiji** [JP/JP]; 4-20, Inarimae, Tsukuba-shi, Ibaraki Pref. 305-0061 (JP). **MASUYA, Keiichi** [JP/JP]; 1-2-1 Tsukuho, Tsukuba-shi, Ibaraki Pref. 300-3257 (JP). **MATSUURA, Naoko** [JP/JP]; 2-4-1-507, Amakubo, Tsukuba-shi, Ibaraki Pref. 305-0005 (JP). **MIYAKE, Takahiro** [JP/JP]; 2-4-1-102,Amakubo, Tsukuba-shi, Ibaraki Pref. 305-0005 (JP). **OHMORI, Osamu** [JP/JP]; 2-4-6-406, Sengen, Tsukuba-shi, Ibaraki Pref. 305-0047 (JP). **UMEMURA, Ichiro** [JP/JP]; 2-3-7-406, Ninomiya, Tsukuba-shi, Ibaraki Pref. 305-0051 (JP). **STEENSMA, Ruo** [CN/US]; 6509 Avenida Manana, La Jolla, CA 92037 (US). **CHOPIUK, Greg** [CA/US]; 10994 West Ocean Air Drive No.387, San Diego, CA 92130 (US). **JIANG, Jiqing** [CN/US]; 5225 Fiore Terrace No.D104, San Diego, CA 92122 (US). **WAN, Yongqin** [CN/US]; 7552 Charmant Drive, No.1622, San Diego, CA 92122 (US). **DING, Qiang** [CN/US]; 8465 Regents Road No 264, San Diego, CA 92122 (US). **ZHANG, Qiong** [CN/US]; 8148 Genesee Ave., No.106, San Diego, CA 92122 (US). **GRAY, Nathanael, Schiander** [US/US]; 5652 Lamas Street, San Diego, CA 92122 (US). **KARANEWSKY, Donald** [US/US]; 1797 Continental Lane, Escondido, CA 92029 (US).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS



(I)


(57) Abstract: Novel pyrimidine derivatives of formula (I) Wherein R is selected from C_{16-10} aryl, $_{C5-10}$heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl; R^0-R^6 as described herein; and their use for the manufacture of a medicament for the treatment or prevention of a disease wich responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR.

WO 2005/016894 A1

2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS.

The present invention relates to the use novel pyrimidine derivatives, the certian novel pyrimidine derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

More particularly the present invention provides in a first aspect, the use of a compound of formula I



(I)

wherein

R is selected from C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl and C_{3-10}heterocycloalkyl;

each of R^0, R^1, R^2,and R^3 independently is hydrogen, C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkinyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkylC_1-C_8alkyl, C_5-C_{10}arylC_1-C_8alkyl, hydroxyC_1-C_8alkyl, C_1-C_8alkoxyC_1-C_8alkyl, aminoC_1-C_8alkyl, haloC_1-C_8alkyl, unsubstituted or substituted C_5-C_{10}aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C_1-C_8alkoxy, hydroxyC_1-C_8alkoxy, C_1-C_8alkoxyC_1-C_8alkoxy, haloC_1-C_8alkoxy, unsubstituted or substituted C_5-C_{10}arylC_1-C_8alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC_1-C_8alkoxy, unsubstitued or substituted amino, C_1-C_8alkylthio, C_1-C_8alkylsulfinyl, C_1-C_8alkylsulfonyl, C_5-C_{10}arylsulfonyl, halogen, carboxy, C_1-C_8alkoxycarbonyl, unsubstitued or substituted carbamoyl, unsubstitued or substituted sulfamoyl, cyano, nitro, $-S(O)_{0-2}NR_{12}R_{13}$, $-S(O)_{0-2}R_{13}$, $-NR_{12}S(O)_{0-2}R_{13}$, $-C(O)NR_{12}R_{13}$, $-C(O)R_{13}$ and $-C(O)OR_{13}$; wherein R_{12} is selected from hydrogen and C_{1-6}alkyl; and R_{13} is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl;

or R^0 and R^1, R^1 and R^2, and/or R^2 and R^3 form, together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S;

R^4 is hydrogen or C_1-C_8alkyl;